-- （更新：Inhibrx已回覆的置評請求。） 根據路透社週三引述知情人士報道，德國默克集團（Merck KGaA）和日本小野藥品工業株式會社（Ono Pharmaceutical）已對Inhibrx Biosciences（INBX）的實驗性抗癌藥物表示出興趣，該藥物估值可能超過80億美元。 知情人士告訴路透社，Inhibrx正在考慮聯合剝離該療法INBRX-106以及另一種實驗性抗癌藥物，如果臨床試驗成功，這兩種藥物的總價值可能超過90億美元。 Inhibrx拒絕就此事向置評，而默克和小野藥品工業株式會社尚未回覆置評請求。 （市場動態新聞來自與全球市場專業人士的對話。這些資訊被認為是來自可靠來源，但可能包含傳聞和猜測。準確性無法保證。）
Price: $112.88, Change: $+0.32, Percent Change: +0.28%
Shandong Hongqiao Aluminum Industry (SHE:002379) reported a 38% jump in attributable net profit in the first quarter of 2026 to 6.76 billion yuan from 4.91 billion yuan, according to a filing on the Shenzhen Stock Exchange over the weekend.Diluted earnings per share rose to 0.5186 yuan from 0.3770 yuan.The aluminum company's revenue edged up 3.21% to 40.9 billion yuan from 39.7 billion yuan.
Cofoe Medical Technology (HKG:1187, SHE:301087) launched its Hong Kong initial public offering on Monday, seeking to raise up to about HK$1.06 billion from the deal.The China-based home care medical device provider is offering 27 million H-shares at a maximum offer price of HK$39.33 per share, according to a Hong Kong bourse filing.The offering comprises 2.7 million shares for Hong Kong investors and 24.3 million shares for international investors, subject to reallocation.The offer price is expected to be determined by May 4, with allocation results due by May 5, ahead of the company's planned trading debut on May 6.Net proceeds will be used mainly to support global expansion and strengthen overseas sales channels, as well as advance product research and development.The funds will also be used to expand domestic distribution networks, enhance branding and marketing efforts, and for working capital and general corporate purposes.Huatai Financial Holdings (Hong Kong) and BNP Paribas Securities (Asia) are acting as joint sponsors.Huatai Financial Holdings (Hong Kong) and BNP Paribas Securities (Asia) are serving as overall coordinators and are also acting as joint bookrunners and joint lead managers, alongside Futu Securities International (Hong Kong).
CMOC Group (SHA:603993, HKG:3993) reported a 97% jump in attributable net profit in the first quarter of 2026 to 7.76 billion yuan from 3.95 billion yuan a year ago, according to filings on the Shanghai and Hong Kong bourses over the weekend.Diluted earnings per share doubled to 0.36 yuan from 0.18 yuan.The copper and cobalt producer's revenue edged up 44% to 66.4 billion yuan from 46 billion yuan.